PL97544B1 - Sposob wytwarzania nowych pochodnych aminoimidazoloizochinoliny - Google Patents
Sposob wytwarzania nowych pochodnych aminoimidazoloizochinoliny Download PDFInfo
- Publication number
- PL97544B1 PL97544B1 PL1973190223A PL19022373A PL97544B1 PL 97544 B1 PL97544 B1 PL 97544B1 PL 1973190223 A PL1973190223 A PL 1973190223A PL 19022373 A PL19022373 A PL 19022373A PL 97544 B1 PL97544 B1 PL 97544B1
- Authority
- PL
- Poland
- Prior art keywords
- group
- compound
- general formula
- carbon atoms
- acid addition
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 8
- 150000001299 aldehydes Chemical class 0.000 claims abstract description 5
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 4
- 150000002576 ketones Chemical class 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical group NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims description 4
- 229910052784 alkaline earth metal Chemical group 0.000 claims description 4
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims description 4
- 125000002560 nitrile group Chemical group 0.000 claims description 4
- 150000001342 alkaline earth metals Chemical group 0.000 claims description 3
- 239000013067 intermediate product Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 239000012458 free base Substances 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 239000003513 alkali Substances 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 15
- 239000001257 hydrogen Substances 0.000 abstract description 5
- 150000002431 hydrogen Chemical class 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- VYSVXRPKWRFJGG-UHFFFAOYSA-N 3h-pyrazolo[3,4-h]isoquinolin-1-amine Chemical class C1=CN=CC2=C3C(N)=NNC3=CC=C21 VYSVXRPKWRFJGG-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000012670 alkaline solution Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 12
- 229910052760 oxygen Inorganic materials 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 8
- 230000010412 perfusion Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 5
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 4
- 210000005240 left ventricle Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- -1 cycloalkyl nickel Chemical compound 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J23/00—Details of transit-time tubes of the types covered by group H01J25/00
- H01J23/02—Electrodes; Magnetic control means; Screens
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J25/00—Transit-time tubes, e.g. klystrons, travelling-wave tubes, magnetrons
- H01J25/34—Travelling-wave tubes; Tubes in which a travelling wave is simulated at spaced gaps
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Microwave Tubes (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUCI1248A HU167240B (es) | 1972-06-30 | 1972-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL97544B1 true PL97544B1 (pl) | 1978-03-30 |
Family
ID=10994443
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL1973193522A PL96818B1 (pl) | 1972-06-30 | 1973-06-29 | Sposob wytwarzania nowych pochodnych aminoimidazoloizochinoliny |
PL1973184279A PL94046B1 (en) | 1972-06-30 | 1973-06-29 | Fused-ring isoquinoline derivatives[gb1438819a] |
PL1973184280A PL94059B1 (en) | 1972-06-30 | 1973-06-29 | Fused-ring isoquinoline derivatives[gb1438819a] |
PL1973184281A PL94060B1 (en) | 1972-06-30 | 1973-06-29 | Fused-ring isoquinoline derivatives[gb1438819a] |
PL1973163721A PL93702B1 (en) | 1972-06-30 | 1973-06-29 | Fused-ring isoquinoline derivatives[gb1438819a] |
PL1973190223A PL97544B1 (pl) | 1972-06-30 | 1973-06-29 | Sposob wytwarzania nowych pochodnych aminoimidazoloizochinoliny |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL1973193522A PL96818B1 (pl) | 1972-06-30 | 1973-06-29 | Sposob wytwarzania nowych pochodnych aminoimidazoloizochinoliny |
PL1973184279A PL94046B1 (en) | 1972-06-30 | 1973-06-29 | Fused-ring isoquinoline derivatives[gb1438819a] |
PL1973184280A PL94059B1 (en) | 1972-06-30 | 1973-06-29 | Fused-ring isoquinoline derivatives[gb1438819a] |
PL1973184281A PL94060B1 (en) | 1972-06-30 | 1973-06-29 | Fused-ring isoquinoline derivatives[gb1438819a] |
PL1973163721A PL93702B1 (en) | 1972-06-30 | 1973-06-29 | Fused-ring isoquinoline derivatives[gb1438819a] |
Country Status (24)
Country | Link |
---|---|
JP (2) | JPS5336480B2 (es) |
AR (5) | AR208055A1 (es) |
AT (1) | AT329058B (es) |
BE (1) | BE801668A (es) |
CA (1) | CA1014559A (es) |
CH (6) | CH603647A5 (es) |
CS (1) | CS179024B1 (es) |
DD (1) | DD108090A1 (es) |
DE (1) | DE2332860C2 (es) |
DK (1) | DK141066B (es) |
EG (1) | EG11302A (es) |
ES (1) | ES416971A1 (es) |
FI (1) | FI55199C (es) |
FR (1) | FR2190458B1 (es) |
GB (1) | GB1438819A (es) |
HU (1) | HU167240B (es) |
IL (1) | IL42613A (es) |
IN (1) | IN139710B (es) |
NL (1) | NL177750C (es) |
NO (1) | NO138908C (es) |
PL (6) | PL96818B1 (es) |
SE (6) | SE405603B (es) |
SU (5) | SU584782A3 (es) |
YU (4) | YU36175B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH603643A5 (es) * | 1976-09-29 | 1978-08-31 | Sandoz Ag | |
HU176214B (en) * | 1977-05-18 | 1981-01-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing new 5,6-dihydro-imidazo-square bracket-5,1-a-square bracket closed-isoquinolin derivatives |
CZ20014099A3 (cs) * | 1999-05-19 | 2002-04-17 | The Procter & Gamble Company | Heterocyklické sloučeniny obsahující imidazolový kruh a farmaceutický prostředek s jejich obsahem |
US6552033B1 (en) | 2000-05-16 | 2003-04-22 | The Procter & Gamble Co. | Imidazo-containing heterocyclic compounds, their compositions and uses |
PT2573073E (pt) * | 2011-09-26 | 2015-02-05 | Sanofi Sa | Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH25A (de) * | 1888-11-16 | 1889-04-05 | Saurer & Soehne F | Maschine zum Einfädeln von Nadeln und zur Fadenverknotung |
-
1972
- 1972-06-30 HU HUCI1248A patent/HU167240B/hu unknown
-
1973
- 1973-01-01 AR AR248881A patent/AR208055A1/es active
- 1973-06-26 IL IL42613A patent/IL42613A/en unknown
- 1973-06-26 SE SE7308998A patent/SE405603B/xx unknown
- 1973-06-27 AT AT563773A patent/AT329058B/de not_active IP Right Cessation
- 1973-06-27 FI FI2054/73A patent/FI55199C/fi active
- 1973-06-28 DK DK357373AA patent/DK141066B/da not_active IP Right Cessation
- 1973-06-28 DE DE2332860A patent/DE2332860C2/de not_active Expired
- 1973-06-28 ES ES416971A patent/ES416971A1/es not_active Expired
- 1973-06-29 CA CA175,341A patent/CA1014559A/en not_active Expired
- 1973-06-29 CH CH1280677A patent/CH603647A5/xx not_active IP Right Cessation
- 1973-06-29 DD DD171938A patent/DD108090A1/xx unknown
- 1973-06-29 JP JP7357473A patent/JPS5336480B2/ja not_active Expired
- 1973-06-29 PL PL1973193522A patent/PL96818B1/pl unknown
- 1973-06-29 NO NO732694A patent/NO138908C/no unknown
- 1973-06-29 PL PL1973184279A patent/PL94046B1/pl unknown
- 1973-06-29 SU SU7301941205A patent/SU584782A3/ru active
- 1973-06-29 YU YU1796/73A patent/YU36175B/xx unknown
- 1973-06-29 CH CH191777A patent/CH602729A5/xx not_active IP Right Cessation
- 1973-06-29 CH CH191977A patent/CH602731A5/xx not_active IP Right Cessation
- 1973-06-29 BE BE132908A patent/BE801668A/xx not_active IP Right Cessation
- 1973-06-29 NL NLAANVRAGE7309104,A patent/NL177750C/xx not_active IP Right Cessation
- 1973-06-29 PL PL1973184280A patent/PL94059B1/pl unknown
- 1973-06-29 FR FR7323956A patent/FR2190458B1/fr not_active Expired
- 1973-06-29 GB GB3117573A patent/GB1438819A/en not_active Expired
- 1973-06-29 CH CH952573A patent/CH603639A5/xx not_active IP Right Cessation
- 1973-06-29 PL PL1973184281A patent/PL94060B1/pl unknown
- 1973-06-29 CH CH191877A patent/CH602730A5/xx not_active IP Right Cessation
- 1973-06-29 PL PL1973163721A patent/PL93702B1/pl unknown
- 1973-06-29 CH CH1359177A patent/CH610900A5/xx not_active IP Right Cessation
- 1973-06-29 PL PL1973190223A patent/PL97544B1/pl unknown
- 1973-06-30 IN IN1533/CAL/73A patent/IN139710B/en unknown
- 1973-06-30 EG EG252/73A patent/EG11302A/xx active
- 1973-07-02 CS CS7300004783A patent/CS179024B1/cs unknown
-
1974
- 1974-12-23 AR AR257053A patent/AR210066A1/es active
-
1975
- 1975-11-21 AR AR261310A patent/AR209330A1/es active
- 1975-11-21 AR AR261311A patent/AR209331A1/es active
-
1976
- 1976-02-24 SU SU762325405A patent/SU587863A3/ru active
- 1976-02-24 SU SU7602325957A patent/SU584783A3/ru active
- 1976-02-24 SU SU762326052A patent/SU591148A3/ru active
- 1976-03-17 AR AR262581A patent/AR211857A1/es active
- 1976-09-14 SE SE7610169A patent/SE410189B/xx not_active IP Right Cessation
- 1976-09-14 SE SE7610170A patent/SE425314B/xx unknown
- 1976-09-14 SE SE7610171A patent/SE410190B/xx not_active IP Right Cessation
- 1976-10-26 SU SU762414099A patent/SU596170A3/ru active
-
1977
- 1977-07-29 JP JP9130377A patent/JPS5334799A/ja active Granted
-
1979
- 1979-12-10 YU YU2995/79A patent/YU36176B/xx unknown
- 1979-12-10 YU YU2994/79A patent/YU36300B/xx unknown
- 1979-12-10 YU YU2996/79A patent/YU36177B/xx unknown
-
1980
- 1980-01-11 SE SE8000253A patent/SE431455B/sv unknown
- 1980-04-02 SE SE8002538A patent/SE420968B/sv not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101596191B (zh) | 用作代谢调节剂的丙二酰基辅酶a脱羧酶抑制剂 | |
PL105962B1 (pl) | Sposob wytwarzania nowych pochodnych tieno/2,3-c/pirydyny | |
US3993656A (en) | 1,8-Naphthyridine compounds | |
US20080161365A1 (en) | Methylene Derivatives | |
CN101402565A (zh) | 卤代2-(a-羟基戊基)苯甲酸盐及其制法和用途 | |
Garg et al. | Potential antineoplastics. I. 2-Amino-4, 6-dimethyl-5-arylazopyrimidines and 1-thiocarbamoyl-3, 5-diphenyl-4-arylazopyrazoles | |
KR930001835B1 (ko) | 신규 히단토인(Hydantoin) 유도체의 제조방법 | |
US3755583A (en) | Chas0!nhx | |
US4465686A (en) | 5-(Hydroxy- and/or amino-phenyl)-6-(lower-alkyl)-2-(1H)-pyridinones, their cardiotonic use and preparation | |
JPS6163667A (ja) | ベンゾキサジノン類,その製法及びそれを含む医薬組成物 | |
US4376768A (en) | Benzothiazine derivative | |
JPS58501377A (ja) | 抗炎症性置換1,2,4−トリアゾロ〔4,3−b〕−1,2,4−トリアジン類 | |
PL97544B1 (pl) | Sposob wytwarzania nowych pochodnych aminoimidazoloizochinoliny | |
US4432981A (en) | 2-(Pyridinyl or hydroxyphenyl)-8-substituted pyrido[2,3-d]pyrimidin-5(8H)-ones | |
Piantadosi et al. | Potential anticancer agents V: The synthesis and biochemical studies of 5‐fluorinated pyrimidine‐6‐carboxaldehydes and derivatives | |
US4524149A (en) | 5-Alkanoyl-6-alkyl-2(1H)-pyridinones, their preparation and their cardiotonic use | |
US4599423A (en) | Preparation of 5-(hydroxy- and/or aminophenyl-6-lower-alkyl)-2(1H)-pyridinones | |
PL131451B1 (en) | Method of obtaining new derivatives of 1,2,4-oxydiazolin-5-one | |
NZ205342A (en) | 2-(1h)-pyridinone derivatives and pharmaceutical compositions | |
US3927000A (en) | 1(OR 3) Perfluoroalkyl-3,4-dihydro-2(1H)-isoquinolinecarbonitriles and intermediates | |
US3555036A (en) | Cyclopropyl-1,2,4-oxadiazolylpyridines | |
EP0194665A1 (en) | beta-Adrenergic receptor agonist alkylaminoalkyl pyridinemethanol derivatives | |
US4473571A (en) | 8-Substituted-2-(4-pyridinyl)-9H-purin-6-amines and their cardiotonic use | |
Bauer et al. | 4-(4-Pyrimidinyl) pyridinium Salts. Analogs of the Hypoglycemic 4-Pyrazolylpyridinium Salts | |
GB2066251A (en) | 3-acylamino-s-(pyridinyl)-2(1h)-pyridinones |